Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
The Helsinki Heart Study
Introduction
Overview
Overview
The Helsinki Heart Study (HHS) is a randomized double-blinded trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfibrozil.
Study Description
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Coronary heart disease |
| Masking | Double blind |
| Study Details | |
| Primary Purpose | Prevention |
| Condition | Primary dyslipidemia |
| Intervention | Gemfibrozil Placebo |
| Population Size | 4081 subjects |
Publications
Publications
The HHS revealed that the treatment with gemfibrozil led to an increase in HDL cholesterol and a decrease in non-HDL cholesterol and triglycerides as compared to placebo. Compared to placebo, gemfibrozil decreased the incidence of coronary heart disease by 32% without any change in the rate of death.[1]
References
References
- ↑ Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P; et al. (1987). “Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease”. N Engl J Med. 317 (20): 1237–45. doi:10.1056/NEJM198711123172001. PMID 3313041.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]